These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 24126616)

  • 1. Skeletal manifestations of treatment of breast cancer on premenopausal women.
    Doo L; Shapiro CL
    Curr Osteoporos Rep; 2013 Dec; 11(4):311-8. PubMed ID: 24126616
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Osteopenia and osteoporosis in women with breast cancer.
    Ramaswamy B; Shapiro CL
    Semin Oncol; 2003 Dec; 30(6):763-75. PubMed ID: 14663777
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Skeletal manifestations of treatment of breast cancer.
    Choksi P; Williams M; Clark PM; Van Poznak C
    Curr Osteoporos Rep; 2013 Dec; 11(4):319-28. PubMed ID: 24132726
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevention and treatment of osteoporosis in women with breast cancer.
    Mincey BA; Moraghan TJ; Perez EA
    Mayo Clin Proc; 2000 Aug; 75(8):821-9. PubMed ID: 10943237
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effects of adjuvant endocrine therapy on bone health in women with breast cancer.
    Ramchand SK; Cheung YM; Yeo B; Grossmann M
    J Endocrinol; 2019 Jun; 241(3):R111-R124. PubMed ID: 30991355
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of ovarian failure and osteoporosis in premenopausal breast cancer survivors.
    McCune JS; Games DM; Espirito JL
    J Oncol Pharm Pract; 2005 Jun; 11(2):37-43. PubMed ID: 16460603
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selective estrogen receptor modulation and reduction in risk of breast cancer, osteoporosis, and coronary heart disease.
    Jordan VC; Gapstur S; Morrow M
    J Natl Cancer Inst; 2001 Oct; 93(19):1449-57. PubMed ID: 11584060
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bone health during endocrine therapy for cancer.
    Rachner TD; Coleman R; Hadji P; Hofbauer LC
    Lancet Diabetes Endocrinol; 2018 Nov; 6(11):901-910. PubMed ID: 29572126
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Premenopausal women with early breast cancer treated with estradiol suppression have severely deteriorated bone microstructure.
    Ramchand SK; Seeman E; Wang XF; Ghasem-Zadeh A; Francis PA; Ponnusamy EJ; Bardin MS; Bui M; Zebaze R; Zajac JD; Grossmann M
    Bone; 2017 Oct; 103():131-135. PubMed ID: 28673637
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preventing osteoporosis in symptomatic postmenopausal women.
    Gallagher JC; Levine JP
    Menopause; 2011 Jan; 18(1):109-18. PubMed ID: 20661164
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hormone- and chemotherapy-induced bone loss in breast cancer.
    Coleman RE
    Oncology (Williston Park); 2004 May; 18(5 Suppl 3):16-20. PubMed ID: 15202583
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanisms of action of antiresorptive therapies of postmenopausal osteoporosis.
    Stepan JJ; Alenfeld F; Boivin G; Feyen JH; Lakatos P
    Endocr Regul; 2003 Dec; 37(4):225-38. PubMed ID: 15106819
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Strategies for the prevention of treatment-related bone loss in women receiving adjuvant hormonal therapy.
    Rugo HS
    Clin Breast Cancer; 2007 Jul; 7 Suppl 1():S21-8. PubMed ID: 17683650
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pros and cons of existing treatment modalities in osteoporosis: a comparison between tibolone, SERMs and estrogen (+/-progestogen) treatments.
    Kloosterboer HJ; Ederveen AG
    J Steroid Biochem Mol Biol; 2002 Dec; 83(1-5):157-65. PubMed ID: 12650712
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of zoledronic acid on bone mineral density in premenopausal women receiving neoadjuvant or adjuvant therapies for HR+ breast cancer: the ProBONE II study.
    Hadji P; Kauka A; Ziller M; Birkholz K; Baier M; Muth M; Bauer M
    Osteoporos Int; 2014 Apr; 25(4):1369-78. PubMed ID: 24504100
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Osteoporosis and breast cancer.
    Fontanges E; Fontana A; Delmas P
    Joint Bone Spine; 2004 Mar; 71(2):102-10. PubMed ID: 15116704
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Specific estrogen receptor modulators (SERMs)].
    Trémollières F; Lopes P
    Presse Med; 2002 Sep; 31(28):1323-8. PubMed ID: 12355995
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacotherapeutics for osteoporosis prevention and treatment.
    Davidson MR
    J Midwifery Womens Health; 2003; 48(1):39-52. PubMed ID: 12589304
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Managing the risk of osteoporosis in women with a history of early breast cancer.
    Ravdin PM
    Oncology (Williston Park); 2004 Oct; 18(11):1385-90, 1393; discussion 1394. PubMed ID: 15609468
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selective estrogen receptor modulators.
    Haskell SG
    South Med J; 2003 May; 96(5):469-76. PubMed ID: 12911186
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.